Polycomb repressive complex 2 mutations predict survival benefit in advanced cancer patients treated with immune checkpoint inhibitors

被引：0
|
作者：
Vlachostergios, P. J. [1 ]
机构：
[1] Weill Cornell Med, Hematol & Med Oncol, New York, NY USA
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.01.035
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
21P
引用
收藏
页码：S9 / S9
页数：1
相关论文
共 50 条
  • [41] A genomics model to predict immune-related adverse events in cancer patients treated with checkpoint inhibitors
    Scott, Emma C.
    Kazandjian, Dickran
    Santana-Quintero, Luis
    Ghazanchyan, Tigran
    Petrovskaya, Svetlana
    Zhang, Yong
    Rosenberg, Amy
    Rao, V. Ashutosh
    Marte, Jennifer L.
    Blumenthal, Gideon M.
    Theoret, Marc R.
    Pazdur, Richard
    Gulley, James L.
    Beaver, Julia A.
    CANCER RESEARCH, 2019, 79 (13)
  • [42] Machine learning algorithms able to predict the prognosis of gastric cancer patients treated with immune checkpoint inhibitors
    Li, Hong-Wei
    Zhu, Zi-Yu
    Sun, Yu-Fei
    Yuan, Chao-Yu
    Wang, Mo-Han
    Wang, Nan
    Xue, Ying-Wei
    WORLD JOURNAL OF GASTROENTEROLOGY, 2024, 30 (40)
  • [43] Changes in lymphocyte/monocyte ratio, prognostic marker to predict overall survival in patients with advanced cancer treated with immune checkpoint inhibitor.
    Patel, Sandip H.
    Li, Mingjia
    Zhao, Songzhu
    Wei, Lai
    Burkart, Jarred Thomas
    Husain, Marium
    He, Kai
    Bertino, Erin Marie
    Shields, Peter G.
    Carbone, David Paul
    Verschraegen, Claire F.
    Otterson, Gregory Alan
    Kendra, Kari Lynn
    Spakowicz, Daniel
    Presley, Carolyn J.
    Owen, Dwight Hall
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [44] Identification of a prognostic immune signature for cervical cancer to predict survival and response to immune checkpoint inhibitors
    Yang, Si
    Wu, Ying
    Deng, Yujiao
    Zhou, Linghui
    Yang, Pengtao
    Zheng, Yi
    Zhang, Dai
    Zhai, Zhen
    Li, Na
    Hao, Qian
    Song, Dingli
    Kang, Huafeng
    Dai, Zhijun
    ONCOIMMUNOLOGY, 2019, 8 (12):
  • [45] PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors
    Minari, Roberta
    Bonatti, Francesco
    Mazzaschi, Giulia
    Dodi, Alessandra
    Facchinetti, Francesco
    Gelsomino, Francesco
    Cinquegrani, Gloria
    Squadrilli, Anna
    Bordi, Paola
    Buti, Sebastiano
    Bersanelli, Melissa
    Leonetti, Alessandro
    Cosenza, Agnese
    Ferri, Leonarda
    Rapacchi, Elena
    Quaini, Federico
    Ardizzoni, Andrea
    Tiseo, Marcello
    TUMORI JOURNAL, 2022, 108 (01): : 47 - 55
  • [46] Long-term survival of patients with advanced non-small cell lung cancer treated using immune checkpoint inhibitors
    Tamiya, Akihiro
    RESPIRATORY INVESTIGATION, 2024, 62 (01) : 85 - 89
  • [47] Association of inflammatory markers with survival in patients with advanced gastric cancer treated with immune checkpoint inhibitors combined with chemotherapy as first line treatment
    Wan, Mingyu
    Ding, Yongfeng
    Mao, Chenyu
    Ma, Xiaolu
    Li, Ning
    Xiao, Cheng
    Qian, Jiong
    Jiang, Haiping
    Zheng, Yulong
    Wu, Luntao
    Teng, Lisong
    Xu, Nong
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [48] Proton pump inhibitor use (PPI) in patients treated with immune checkpoint inhibitors (ICI) for advanced cancer: Survival and prior therapy.
    Husain, Marium
    Xu, Menglin
    Patel, Sandipkumar
    Johns, Andrew
    Grogan, Madison
    Li, Mingjia
    Lopez, Gabrielle
    Miah, Abdul
    Hoyd, Rebecca
    Liu, YunZhou
    Muniak, Mitchell
    Haddad, Tyler
    Tinoco, Gabriel
    Kendra, Kari Lynn
    Otterson, Gregory Alan
    Presley, Carolyn J.
    Spakowicz, Daniel
    Owen, Dwight Hall
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [49] Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors
    Elkrief, Arielle
    El Raichani, Layal
    Richard, Corentin
    Messaoudene, Meriem
    Belkaid, Wiam
    Malo, Julie
    Belanger, Karl
    Miller, Wilson
    Jamal, Rahima
    Letarte, Nathalie
    Wong, Philip
    Routy, Bertrand
    ONCOIMMUNOLOGY, 2019, 8 (04):
  • [50] Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors
    Mantia, Charlene M. M.
    Werner, Lillian
    Stwalley, Brian
    Ritchings, Corey
    Tarhini, Ahmad A. A.
    Atkins, Michael B. B.
    McDermott, David F. F.
    Regan, Meredith M. M.
    MELANOMA RESEARCH, 2022, 32 (01) : 35 - 44
12345